Immunovia Valuation Multiples

Immunovia Overview

About Immunovia

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Founded

2007

HQ

Employees

9

Website

immunovia.com

Sectors

Medical Imaging & DiagnosticsHealthTech

Financials (LTM)

Revenue: $198K

EBITDA: ($9M)

EV

$9M

Valuation Multiples

Multiples.vc

Start free trial

Immunovia Financials

Immunovia reported last 12-month revenue of $198K and negative EBITDA of ($9M).

In the same LTM period, Immunovia generated $133K in gross profit, ($9M) in EBITDA losses, and had net loss of ($15M).

Immunovia P&L

In the most recent fiscal year, Immunovia reported revenue of $77K and EBITDA of ($9M).

Immunovia expects next 12-month revenue of XXX and NTM EBITDA of XXX

Immunovia Stock Performance

Immunovia has current market cap of $17M, and enterprise value of $9M.

Immunovia's stock price is $0.03.

Immunovia Valuation Multiples

Immunovia trades at 44.8x EV/Revenue multiple, and (1.0x) EV/EBITDA.

Immunovia Financial Valuation Multiples

As of April 19, 2026, Immunovia has market cap of $17M and EV of $9M.

Equity research analysts estimate Immunovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immunovia has a P/E ratio of (1.2x).

Immunovia Margins & Growth Rates

Immunovia's revenue in the last 12 month grew by 444%.

Immunovia's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Immunovia's rule of 40 is (1727%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Immunovia's rule of X is (909%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Immunovia Public Comps

See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.

Immunovia M&A Activity

Immunovia acquired XXX companies to date.

Last acquisition by Immunovia was on XXXXXXXX, XXXXX. Immunovia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Immunovia Investment Activity

Immunovia invested in XXX companies to date.

Immunovia made its latest investment on XXXXXXXX, XXXXX. Immunovia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).